Annals of Hematology

, Volume 92, Issue 5, pp 621–631

High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM

  • C. Kelaidi
  • O. Beyne-Rauzy
  • T. Braun
  • R. Sapena
  • P. Cougoul
  • L. Adès
  • F. Pillard
  • C. Lambert
  • J. C. Charniot
  • A. Guerci
  • B. Choufi
  • A. Stamatoullas
  • B. Slama
  • B. De Renzis
  • S. Ame
  • G. Damaj
  • F. Boyer
  • M. P. Chaury
  • L. Legros
  • S. Cheze
  • A. Testu
  • E. Gyan
  • M. C. Béné
  • C. Rose
  • F. Dreyfus
  • P. Fenaux
Original Article

Abstract

Darbepoetin (DAR), with or without granulocyte colony-stimulating factor (G-CSF), has proved effective in treating anemia in patients with lower-risk myelodysplastic syndrome (MDS), but its effects on quality of life (QoL) and exercise functioning are less well established. In this phase II study (no. NCT00443339), lower-risk MDS patients with anemia and endogenous erythropoietin (EPO) level <500 IU/L received DAR 500 μg once every 2 weeks for 12 weeks, with G-CSF added at week 12 in non-responders. Physical performance was assessed with the 6-min walking test and, for fit patients, maximal oxygen consumption (VO2max). QoL was evaluated using SF-36 and FACT-An tests. In 99 patients, erythroid response rate according to IWG 2006 criteria was 48 and 56 % at 12 and 24 weeks, respectively. Addition of G-CSF rescued 22 % of non-responders. In 48 % of the responders, interval between darbepoetin injections could be increased for maintenance treatment. Serum EPO level was the only independent predictive factor of response at 12 weeks, and its most discriminant cutoff value was 100 IU/L. QoL and VO2max showed improvement over time in responders, compared with non-responders. With a median follow-up of 52 months, median response duration was not reached, and 3-year cumulative incidence of acute myeloid leukemia and overall survival (OS) was 14.5 and 70 %, respectively. Baseline transfusion dependence, International Prognostic Score System (IPSS), and Revised IPSS accurately predicted OS from treatment onset. Tolerance of darbepoetin was good. In conclusion, this regimen of darbepoetin every 2 weeks yielded high response rates and prolonged response duration. Objective improvement in exercise testing and in patient-reported QoL confirms the clinical relevance of anemia correction with erythropoiesis-stimulating agents.

Keywords

Darbepoetin Myelodysplastic syndromes Anemia Quality of life Exercise capacity 

Supplementary material

277_2013_1686_MOESM1_ESM.docx (112 kb)
ESM 1(DOCX 111 kb)

References

  1. 1.
    Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199PubMedGoogle Scholar
  2. 2.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, LyonGoogle Scholar
  3. 3.
    Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes (see comment) (erratum appears in Blood 1998 Feb 1;91:1100). Blood 89:2079–2088PubMedGoogle Scholar
  4. 4.
    Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA (2002) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95:888–895PubMedCrossRefGoogle Scholar
  5. 5.
    Nilsson-Ehle H, Birgegård G, Samuelsson J, Antunovic P, Astermark J, Garelius H, Engström LM, Kjeldsen L, Nilsson L, Olsson A, Skov-Holm M, Wallvik J, Gulbrandsen N, Hellström-Lindberg E (2011) Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions. Eur J Haematol 87:244–252PubMedCrossRefGoogle Scholar
  6. 6.
    Hellstrom-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J, Ost A, Greenberg P (1997) Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 99:344–351PubMedCrossRefGoogle Scholar
  7. 7.
    Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarré MC, Damaj G, Giraudier S, Guerci A, Laurent G, Dombret H, Chomienne C, Ribrag V, Stamatoullas A, Marie JP, Vekhoff A, Maloisel F, Navarro R, Dreyfus F, Fenaux P (2004) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104:321–327PubMedCrossRefGoogle Scholar
  8. 8.
    Spiriti MA, Latagliata R, Niscola P, Cortelezzi A, Francesconi M, Ferrari D, Volpe E, Clavio M, Grossi A, Reyes MT, Musto P, Mitra ME, Azzara A, Pagnini D, D’Arena G, Spadano A, Balleari E, Pecorari P, Capochiani E, De Biasi E, Perego D, Monarca B, Pisani F, Scaramella G, Petti MC (2005) Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 84:167–176PubMedCrossRefGoogle Scholar
  9. 9.
    Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, Coiteux V, Leroux G, Lepelley P, Daniel MT, Cheze S, Mahé B, Ferrant A, Ravoet C, Escoffre-Barbe M, Adès L, Vey N, Aljassem L, Stamatoullas A, Mannone L, Dombret H, Bourgeois K, Greenberg P, Fenaux P, Dreyfus F, GFM group Groupe Francophone des Myélodysplasies (2008) Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 111:574–582PubMedCrossRefGoogle Scholar
  10. 10.
    Jädersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, Pascutto C, Porwit A, Cazzola M, Hellström-Lindberg E (2008) Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 26:3607–3613PubMedCrossRefGoogle Scholar
  11. 11.
    Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, Paietta E, van der Jagt R, Houston J, Thomas ML, Cella D, Rowe JM (2009) Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the Eastern Cooperative Oncology Group (E1996). Blood 114:2393–2400PubMedCrossRefGoogle Scholar
  12. 12.
    Stasi R, Abruzzese E, Lanzetta G, Terzoli E, Amadori S (2005) Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 16:1921–1927PubMedCrossRefGoogle Scholar
  13. 13.
    Musto P, Lanza F, Balleari E, Grossi A, Falcone A, Sanpaolo G, Bodenizza C, Scalzulli PR, La Sala A, Campioni D, Ghio R, Cascavilla N, Carella AM (2005) Darbepoetin alfa for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 128:204–209PubMedCrossRefGoogle Scholar
  14. 14.
    Giraldo P, Nomdedeu B, Loscertales J, Requena C, de Paz R, Tormo M, Navarro P, Benedit P, Gasquet JA, Aranesp in Myelodysplastic Syndromes (ARM) Study Group (2006) Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer 107:2807–2816PubMedCrossRefGoogle Scholar
  15. 15.
    Mannone L, Gardin C, Quarre MC, Bernard JF, Vassilieff D, Ades L, Park S, Vaultier S, Hamza F, Beyne-Rauzy MO, Cheze S, Giraudier S, Agape P, Legros L, Voillat L, Dreyfus F, Fenaux P (2006) High-dose darbepoetin alfa in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 133:513–519PubMedCrossRefGoogle Scholar
  16. 16.
    Gabrilove J, Paquette R, Lyons RM, Mushtaq C, Sekeres MA, Tomita D, Dreiling L (2008) Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 142:379–393PubMedCrossRefGoogle Scholar
  17. 17.
    Gotlib J, Lavori P, Quesada S, Stein RS, Shahnia S, Greenberg PL (2009) A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. Am J Hematol 84:15–20PubMedCrossRefGoogle Scholar
  18. 18.
    Oliva EN, Nobile F, Alimena G, Specchia G, Danova M, Rovati B, Ronco F, Impera S, Risitano A, Alati C, Breccia M, Carmosino I, Vincelli I, Latagliata R (2010) Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. Leukemia & Lymphoma 51:1007–1014CrossRefGoogle Scholar
  19. 19.
    Villegas A, Arrizabalaga B, Fernández-Lago C, Castro M, Mayans JR, González-Porras JR, Duarte RF, Remacha AF, Luño E, Gasquet JA (2011) Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response. Curr Med Res Opin 27:951–960PubMedCrossRefGoogle Scholar
  20. 20.
    AFSSAPS (2002) Transfusion de globules rouges homologues: products, indications, alternatives. Recommendations. Agence Française de Sécurité Sanitaire des Produits de Sante, ParisGoogle Scholar
  21. 21.
    Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419–425PubMedCrossRefGoogle Scholar
  22. 22.
    Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D (2012) Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 120:2454–2465PubMedCrossRefGoogle Scholar
  23. 23.
    Albouaini K, Egred M, Alahmar A, Wright DJ (2007) Cardiopulmonary exercise testing and its application. Heart 93:1285–1292PubMedGoogle Scholar
  24. 24.
    Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, Berman LB (1985) The six-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 132:919–923PubMedGoogle Scholar
  25. 25.
    Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA, Wallace RB (1994) A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 49:M85–M94PubMedCrossRefGoogle Scholar
  26. 26.
    Medelli J (1998) Les épreuves d'effort en médecine du sport. Sci Sports 13:174–187CrossRefGoogle Scholar
  27. 27.
    Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13:63–74PubMedCrossRefGoogle Scholar
  28. 28.
    Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24:547–561PubMedCrossRefGoogle Scholar
  29. 29.
    Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  30. 30.
    Peto R, Peto J (1972) Asymptotically efficient rank invariant test procedures. J R Stat Soc A 135:185–198CrossRefGoogle Scholar
  31. 31.
    Fine J, Gray R (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509CrossRefGoogle Scholar
  32. 32.
    Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Löwenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL, World Health Organization (WHO) international working group (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671–3674PubMedGoogle Scholar
  33. 33.
    Kelaidi C, Stamatoullas A, Beyne-Rauzy O, Raffoux E, Quesnel B, Guerci A, Dreyfus F, Brechignac S, Berthou C, Prebet T, Hicheri Y, Hacini M, Delaunay J, Gourin MP, Camo JM, Zerazhi H, Taksin AL, Legros L, Choufi B, Fenaux P, Groupe Francophone des Myélodysplasies (2010) Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies. Haematologica 95:892–899PubMedCrossRefGoogle Scholar
  34. 34.
    Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V (2009) An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer 115:706–715PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • C. Kelaidi
    • 1
  • O. Beyne-Rauzy
    • 1
  • T. Braun
    • 1
  • R. Sapena
    • 1
  • P. Cougoul
    • 1
  • L. Adès
    • 1
  • F. Pillard
    • 1
  • C. Lambert
    • 1
  • J. C. Charniot
    • 1
  • A. Guerci
    • 1
  • B. Choufi
    • 1
  • A. Stamatoullas
    • 1
  • B. Slama
    • 1
  • B. De Renzis
    • 1
  • S. Ame
    • 1
  • G. Damaj
    • 1
  • F. Boyer
    • 1
  • M. P. Chaury
    • 1
  • L. Legros
    • 1
  • S. Cheze
    • 1
  • A. Testu
    • 1
  • E. Gyan
    • 1
  • M. C. Béné
    • 1
  • C. Rose
    • 1
  • F. Dreyfus
    • 1
  • P. Fenaux
    • 1
  1. 1.GFM Service d’Hématogie Clinique, Hôpital Avicenne, Assistance Publique des Hôpitaux de ParisUniversité Paris 13BobignyFrance

Personalised recommendations